Trial
NCT00723658
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
SWOG Cancer Research Network
Collaborators
National Cancer Institute (NCI)
Condition
Lymphoma
Intervention
rituximab
Why stopped
lack of accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-03-06